Adial Pharmaceuticals announces FDA granted request for End of Phase 2 meeting

Adial Pharmaceuticals (ADIL) announced that the FDA has granted Adial’s request for an End of Phase 2 meeting to discuss Adial’s proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.